These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

955 related items for PubMed ID: 29187493

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
    Pracht M, Mogha A, Lespagnol A, Fautrel A, Mouchet N, Le Gall F, Paumier V, Lefeuvre-Plesse C, Rioux-Leclerc N, Mosser J, Oger E, Adamski H, Galibert MD, Lesimple T.
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
    [Abstract] [Full Text] [Related]

  • 4. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
    Zebary A, Omholt K, Vassilaki I, Höiom V, Lindén D, Viberg L, Kanter-Lewensohn L, Johansson CH, Hansson J.
    J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
    Moltara ME, Novakovic S, Boc M, Bucic M, Rebersek M, Zadnik V, Ocvirk J.
    Radiol Oncol; 2018 Apr 26; 52(3):289-295. PubMed ID: 30210039
    [Abstract] [Full Text] [Related]

  • 7. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
    Kirchberger MC, Ugurel S, Mangana J, Heppt MV, Eigentler TK, Berking C, Schadendorf D, Schuler G, Dummer R, Heinzerling L.
    Eur J Cancer; 2018 Jul 26; 98():10-16. PubMed ID: 29843107
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis.
    Kodali N, Bhattaru A, Blanchard I, Sharma Y, Lipner SR.
    Melanoma Res; 2024 Oct 01; 34(5):419-428. PubMed ID: 38564430
    [Abstract] [Full Text] [Related]

  • 11. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
    Lyu J, Wu Y, Li C, Wang R, Song H, Ren G, Guo W.
    J Oral Pathol Med; 2016 Apr 01; 45(4):295-301. PubMed ID: 26399561
    [Abstract] [Full Text] [Related]

  • 12. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M, Bajah A, Podewski T, Kreuzberg N, von Bartenwerffer W, Wardelmann E, Merkelbach-Bruse S, Büttner R, Mauch C, Kurschat P.
    Br J Dermatol; 2013 Apr 01; 168(4):708-16. PubMed ID: 23528057
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.
    Carlino MS, Haydu LE, Kakavand H, Menzies AM, Hamilton AL, Yu B, Ng CC, Cooper WA, Thompson JF, Kefford RF, O'Toole SA, Scolyer RA, Long GV.
    Br J Cancer; 2014 Jul 15; 111(2):292-9. PubMed ID: 24918823
    [Abstract] [Full Text] [Related]

  • 15. BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients.
    Dika E, Veronesi G, Altimari A, Riefolo M, Ravaioli GM, Piraccini BM, Lambertini M, Campione E, Gruppioni E, Fiorentino M, Melotti B, Ferracin M, Patrizi A.
    Am J Clin Pathol; 2020 Apr 15; 153(5):664-671. PubMed ID: 32017841
    [Abstract] [Full Text] [Related]

  • 16. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B, Akalin T, Kandiloğlu G.
    Am J Dermatopathol; 2015 May 15; 37(5):389-97. PubMed ID: 25357015
    [Abstract] [Full Text] [Related]

  • 17. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
    Heppt MV, Siepmann T, Engel J, Schubert-Fritschle G, Eckel R, Mirlach L, Kirchner T, Jung A, Gesierich A, Ruzicka T, Flaig MJ, Berking C.
    BMC Cancer; 2017 Aug 10; 17(1):536. PubMed ID: 28797232
    [Abstract] [Full Text] [Related]

  • 18. The molecular profile of metastatic melanoma in Australia.
    Lyle M, Haydu LE, Menzies AM, Thompson JF, Saw RP, Spillane AJ, Kefford RF, Mann GJ, Cooper WA, Yu B, Scolyer RA, O'Toole SA, Long GV.
    Pathology; 2016 Feb 10; 48(2):188-93. PubMed ID: 27020391
    [Abstract] [Full Text] [Related]

  • 19. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
    van Engen-van Grunsven AC, Küsters-Vandevelde HV, De Hullu J, van Duijn LM, Rijntjes J, Bovée JV, Groenen PJ, Blokx WA.
    Gynecol Oncol; 2014 Jul 10; 134(1):10-4. PubMed ID: 24802725
    [Abstract] [Full Text] [Related]

  • 20. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V.
    Magy Onkol; 2013 Jun 10; 57(2):96-9. PubMed ID: 23795354
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.